bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) and Acadia Healthcare (NASDAQ:ACHC – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.
Risk and Volatility
bioAffinity Technologies has a beta of -1.11, suggesting that its stock price is 211% less volatile than the S&P 500. Comparatively, Acadia Healthcare has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
Valuation & Earnings
This table compares bioAffinity Technologies and Acadia Healthcare”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| bioAffinity Technologies | $6.16 million | 1.49 | -$14.91 million | ($109.45) | -0.14 |
| Acadia Healthcare | $3.31 billion | 0.79 | -$1.10 billion | ($12.45) | -2.26 |
bioAffinity Technologies has higher earnings, but lower revenue than Acadia Healthcare. Acadia Healthcare is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
1.6% of bioAffinity Technologies shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by insiders. Comparatively, 1.2% of Acadia Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for bioAffinity Technologies and Acadia Healthcare, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| bioAffinity Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Acadia Healthcare | 2 | 5 | 7 | 1 | 2.47 |
Acadia Healthcare has a consensus price target of $29.85, indicating a potential upside of 6.10%. Given Acadia Healthcare’s stronger consensus rating and higher probable upside, analysts plainly believe Acadia Healthcare is more favorable than bioAffinity Technologies.
Profitability
This table compares bioAffinity Technologies and Acadia Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| bioAffinity Technologies | -257.30% | -220.52% | -136.76% |
| Acadia Healthcare | -33.44% | 6.19% | 2.42% |
Summary
Acadia Healthcare beats bioAffinity Technologies on 10 of the 15 factors compared between the two stocks.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
About Acadia Healthcare
Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
